- Conditions
- Plaque Psoriasis
- Interventions
- Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • North Little Rock, Arkansas + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 59
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Arthritis, Rheumatoid
- Interventions
- GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 46
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
- Conditions
- Moderate to Severe Chronic Plaque-Type Psoriasis
- Interventions
- AIN457 150 mg, AIN457 300 mg, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 28
- States / cities
- Fresno, California • Pasadena, California • San Francisco, California + 24 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- secukinumab
- Biological
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- Mirikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Cypress, California • Daytona Beach, Florida • Miami, Florida + 2 more
- Conditions
- Psoriatic Arthritis
- Interventions
- AIN457 (secukinumab), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Omalizumab Injection, Xolair Prefilled Syringe
- Drug
- Lead sponsor
- Kashiv BioSciences, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
- Conditions
- Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
- Interventions
- Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Carlsbad, California • Miami, Florida • Tampa, Florida + 11 more
- Conditions
- Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Interventions
- VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 17
- States / cities
- Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
- Conditions
- Healthy
- Interventions
- Sirukumab (IV infusion), Sirukumab (SC injection with PFS-U), Sirukumab (SC injection with PFS-AI)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Lincoln, Nebraska
- Conditions
- Healthy
- Interventions
- LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
- Biological · Drug · Device
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Thyroid Eye Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
- Conditions
- Healthy Volunteers
- Interventions
- Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • Grayslake, Illinois • Las Vegas, Nevada + 1 more
- Conditions
- Primary Hypercholesterolemia, Mixed Dyslipidemia
- Interventions
- Evolocumab Pre-filled Syringe, Evolocumab AI/pen
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 21
- States / cities
- Encino, California • Thousand Oaks, California • Ventura, California + 17 more
- Conditions
- Asthma
- Interventions
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
- Biological · Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
- Conditions
- REM Sleep Behavior Disorder
- Interventions
- Adalimumab, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Aurora, Colorado • North Haven, Connecticut + 14 more
- Conditions
- Giant Cell Arteritis
- Interventions
- Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more
- Conditions
- Healthy Adult Subjects
- Interventions
- Pegilodecakin
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Acute Gouty Arthritis
- Interventions
- Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 69
- States / cities
- Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- GA 20 mg/mL, GA 40 mg/mL
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 35
- States / cities
- Cullman, Alabama • Gilbert, Arizona • Phoenix, Arizona + 31 more
- Conditions
- Healthy, Multiple Sclerosis
- Interventions
- BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS), BIIB017 (peginterferon beta-1a) Autoinjector
- Device
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- FYB203 2 mg (0.05 mL of 40 mg/mL)
- Drug
- Lead sponsor
- Formycon AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Campbell, California • Long Beach, California • Redlands, California + 1 more
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
- Interventions
- 40 mg MSB11022
- Drug
- Lead sponsor
- Fresenius Kabi SwissBioSim GmbH
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah